BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

NCT06854003 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma
Lymphoma

Interventions

DRUG: Bendamustine
DRUG: Rituximab
DRUG: Cytarabine
DRUG: Zanubrutinib
DRUG: Sonrotoclax

Sponsor

Christine Ryan

Collaborators

[object Object]